Solution to accelerate drug discovery process by DDI analysis

The PharmaPendium DMPK (Drug Metabolism-Pharmacokinetic) solution features a DDI risk calculator that enables earlier and more complete risk mitigation strategies for potential drug-drug interactions.

PharmaPendium for informed decision making

PharmaPendium DMPK informs preclinical and clinical risk/benefit analyses – enabling researchers to make quick evaluations regarding which drug candidates to progress. The DMPK solution also includes a drug-drug interaction risk calculator (DDIRC) that complies with 2012 FDA guidelines on Industry Drug Interaction Studies. Together, the solutions support informed and accelerated decision-making.

Early DDI analysis is critical

In drug discovery and development, early and ongoing assessment of DDIs is critical. Undetected DDIs can lead to severe side effects, resulting in the refusal of regulatory approval, severe prescribing restrictions, or the complete withdrawal of drugs from the market. The FDA reports that between 1995 and 2010, the proportion of adults that dispensed five or more drugs doubled to 20.8% and the proportion dispensed ten or more tripled to 5.8%. DDIs account for between 3-5% of all reported adverse drug events – and with an aging population and the increasing trend towards polypharmacy, are an urgent concern.

PharmaPendium’s DMPK solution provides a unique source of searchable pharmacokinetic, metabolising enzyme and transporter data and, together with DDIRC, allows users to predict potential interactions between an investigational drug and multiple drugs simultaneously – providing a full risk profile against marketed drugs.

“PharmaPendium’s DMPK and DDIRC tools have had a significant impact on our drug development decisions,” commented a senior DMPK scientist from a top pharma company that beta-tested the solution.

“For all scientists and researchers, patient safety is the paramount concern. Currently, identifying and assessing potential DDIs is an essential but resource-intensive task,” said Guenther Kurapkat, Senior Vice President of Life Science Solutions, Elsevier.

This allows them to quickly and confidently prioritise the safest, most promising candidates for further development – and also supports more intelligent and safe clinical trial design.”